secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aclaris Therapeutics, Inc. (ACRS)
CIK:        0001557746
Form:       8-K
Filed at:   2023-11-06T23:59:59+00:00
Accession:  0001558370-23-017655
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aclaris Q3 net loss $29.3M, revenue $9.3M; zunsemetinib RA data due Nov 2023
----------------------------------------------------------------------------

- Net loss of $29.3M for Q3 2023 compared to $20.0M in Q3 2022.
- Total revenue $9.3M, down from $19.0M due to prior year Lilly payment.
- Cash and securities $187.0M as of Sept 30, 2023; sufficient through end of 2025.
- Zunsemetinib Phase 2b RA topline data expected November 2023.
- ATI-1777 Phase 2b AD data expected around year-end 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1557746/000155837023017655/0001558370-23-017655-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1557746/000155837023017655/acrs-20231106x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-017655

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer